CERO THERAPEUTICS HOLDINGS I (CERO) Stock Price, Forecast & Analysis
NASDAQ:CERO • US71902K4022
CERO Key Statistics, Chart & Performance
The current stock price of CERO is 0.0951 USD. In the past month the price decreased by -98.24%. In the past year, price decreased by -99.94%.
CERO Technical Analysis
CERO Financial Highlights
Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -675.76% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Forecast & Estimates
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
CERO Ownership
CERO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 397.325B | ||
| AMGN | AMGEN INC | 16.63 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.62 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CERO
Company Profile
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Phone: 6504072376
CERO THERAPEUTICS HOLDINGS I / CERO FAQ
What does CERO do?
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Can you provide the latest stock price for CERO THERAPEUTICS HOLDINGS I?
The current stock price of CERO is 0.0951 USD. The price decreased by -94.69% in the last trading session.
What is the dividend status of CERO THERAPEUTICS HOLDINGS I?
CERO does not pay a dividend.
What is the ChartMill rating of CERO THERAPEUTICS HOLDINGS I stock?
CERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about CERO THERAPEUTICS HOLDINGS I (CERO) stock?
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
Can you provide the sector and industry classification for CERO THERAPEUTICS HOLDINGS I?
CERO THERAPEUTICS HOLDINGS I (CERO) operates in the Health Care sector and the Biotechnology industry.